FHD-909 Stops Before Expansion

Company Foghorn Therapeutics / Eli Lilly Event Type Clinical / Portfolio Discontinuation Modality Small Molecule Allosteric ATPase Inhibitor Asset FHD-909 (LY4050784) Target SMARCA2/BRM Disease Area SMARCA4-Deficient Non-Small-Cell Lung Cancer Summary Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline